In this Issue
VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control
A Look at the Latest Oregon Psilocybin Services Complaints
Zuranolone’s MDD Journey Ends
Tryp Therapeutics Raises $6M to Forward IV Psilocin Candidate
Psylo and Co. Win $3M Grant to Develop Neuroplastogens
Other Stories
***
VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Subscribe AnnuallySubscribe Monthly
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space✓ Regular articles and deep dives across psychedelic research, policy and business✓ Interviews with insiders✓ Monthly interactive database and commentary on psychedelic patents✓ Quick-take analysis of major developments✓ A Library of primers and explainers✓ Access to our full back catalogue
Learn more about Pα+
